Mae O Gordon1, Michael A Kass2. 1. Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri. 2. Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri. Electronic address: Kass@wustl.edu.
Abstract
PURPOSE: To identify results from the Ocular Hypertension Study that can aid patients and clinicians to make evidence-based decisions about the management of ocular hypertension. DESIGN: Perspective. RESULTS: At 60 months, the cumulative frequency of developing primary open-angle glaucoma (POAG) was 4.4% in the medication group and 9.5% in the observation group (hazard ratio for medication, 0.40; 95% confidence interval [CI], 0.27-0.59; P < .0001). At 13 years the cumulative proportion of participants who developed POAG was 0.22 (95% CI 0.19-0.25) in the original observation group and 0.16 (95% CI 0.13-0.19) in the original medication group (complementary log-log x2P = .009). A 5-factor model (older age, higher IOP, thinner central corneal thickness, larger cup-to-disc ratio, and higher visual field pattern standard deviation) separated participants at high and low risk of developing POAG. CONCLUSIONS: Clinicians and patients can make evidence-based decisions about the management of ocular hypertension using the risk model and considering patient age, medical status, life expectancy, and personal preference.
PURPOSE: To identify results from the Ocular Hypertension Study that can aid patients and clinicians to make evidence-based decisions about the management of ocular hypertension. DESIGN: Perspective. RESULTS: At 60 months, the cumulative frequency of developing primary open-angle glaucoma (POAG) was 4.4% in the medication group and 9.5% in the observation group (hazard ratio for medication, 0.40; 95% confidence interval [CI], 0.27-0.59; P < .0001). At 13 years the cumulative proportion of participants who developed POAG was 0.22 (95% CI 0.19-0.25) in the original observation group and 0.16 (95% CI 0.13-0.19) in the original medication group (complementary log-log x2P = .009). A 5-factor model (older age, higher IOP, thinner central corneal thickness, larger cup-to-disc ratio, and higher visual field pattern standard deviation) separated participants at high and low risk of developing POAG. CONCLUSIONS: Clinicians and patients can make evidence-based decisions about the management of ocular hypertension using the risk model and considering patient age, medical status, life expectancy, and personal preference.
Authors: Michael A Kass; Mae O Gordon; Feng Gao; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John K Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson Journal: Arch Ophthalmol Date: 2010-03
Authors: Felipe A Medeiros; Robert N Weinreb; Pamela A Sample; Cintia F Gomi; Christopher Bowd; Jonathan G Crowston; Linda M Zangwill Journal: Arch Ophthalmol Date: 2005-10
Authors: H M Leibowitz; D E Krueger; L R Maunder; R C Milton; M M Kini; H A Kahn; R J Nickerson; J Pool; T L Colton; J P Ganley; J I Loewenstein; T R Dawber Journal: Surv Ophthalmol Date: 1980 May-Jun Impact factor: 6.048
Authors: Mae O Gordon; Julia A Beiser; James D Brandt; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Michael A Kass Journal: Arch Ophthalmol Date: 2002-06
Authors: Michael A Kass; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Mae O Gordon Journal: Arch Ophthalmol Date: 2002-06
Authors: Eve J Higginbotham; Mae O Gordon; Julia A Beiser; Michael V Drake; G Richard Bennett; M Roy Wilson; Michael A Kass Journal: Arch Ophthalmol Date: 2004-06
Authors: Nathan G Congdon; Aimee T Broman; Karen Bandeen-Roche; Davinder Grover; Harry A Quigley Journal: Am J Ophthalmol Date: 2006-03-09 Impact factor: 5.258
Authors: José Camara; Alexandre Neto; Ivan Miguel Pires; María Vanessa Villasana; Eftim Zdravevski; António Cunha Journal: Diagnostics (Basel) Date: 2022-04-08
Authors: Daniel Laroche; Kara Rickford; Elise V Mike; Liane Hunter; Ezekiel Ede; Chester Ng; John Douglas Journal: J Ophthalmol Date: 2022-07-31 Impact factor: 1.974
Authors: Jan Luebke; Daniel Boehringer; Alexandra Anton; Moritz Daniel; Thomas Reinhard; Stefan Lang Journal: Clin Epidemiol Date: 2021-07-13 Impact factor: 4.790